Why the study?
Coronavirus infections pose a global health threat, motivating the development of broadly active antiviral fusion proteins based on IgM scaffolds.
Hexameric ACE2-IgM-Fc fusion proteins potently neutralize SARS-CoV-2 variants, including omicron, with up to 96-fold greater potency than monomeric forms.
Answers are grounded in this paper and cite their sources.
Advances multivalent ACE2 constructs preclinically; animal data leave open human translation for SARS-CoV-2.
Coronavirus infections are a world-wide threat to human health. A promising strategy to develop a broadly active antiviral is the use of fusion proteins consisting of an antibody IgG Fc region and a human ACE2 domain to which the viral spike proteins bind. Here we create antiviral fusion proteins based on IgM scaffolds. The hexameric ACE2-IgM-Fc fusions can be efficiently produced in mammalian cells and they neutralize the infectious virus with picomolar affinity thus surpassing monomeric ACE2-IgM-Fc by up to 96-fold in potency. In addition, the ACE2-IgM fusion shows increased neutralization efficiency for the highly infectious SARS-CoV-2 omicron variant in comparison to prototypic SARS-CoV-2. Taken together, these multimeric IgM fusions proteins are a powerful weapon to fight coronavirus infections.
No takes yet. Share an insight, caveat, or question.
Svilenov et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: